Blogs

Pharmaceutical products are expected to remain safe, effective, and stable throughout their labeled shelf life. Achieving this objective requires more than a robust drug formulation; the packaging system must also maintain product quality, stability, and, where applicable, sterility from the time the product is manufactured until the end of its intended shelf life. Whether stored at room temperature, refrigerated, or frozen, the package serves as the primary barrier between the pharmaceutical product and the external environment.

As manufacturers pursue longer shelf-life claims to improve supply chain flexibility, reduce waste, and support global distribution, package performance becomes increasingly important. Even microscopic defects in a container closure system may provide pathways for the ingress of moisture, oxygen, microorganisms, or other environmental contaminants, potentially affecting product quality over time. Comprehensive package evaluation—including Container Closure Integrity Testing (CCIT)—helps manufacturers assess whether packaging systems can maintain their intended performance throughout storage and under anticipated environmental conditions.

Understanding Extended Shelf-Life Claims

An extended shelf-life claim indicates that a pharmaceutical product has been demonstrated to remain within its approved quality specifications for a longer storage period than previously established. These claims are supported by scientific evidence generated through stability studies, packaging evaluations, analytical testing, and validation activities.

Shelf-life determination considers multiple quality attributes, including potency, purity, sterility, appearance, and chemical stability. Since the packaging system directly influences many of these attributes, its ability to resist leakage and environmental exposure becomes an important aspect of shelf-life assessment. Any compromise in container closure integrity may accelerate product degradation or increase the risk of contamination during storage and distribution.

For products intended for global distribution, extended shelf-life claims also help accommodate longer shipping times, inventory management, and storage under varying environmental conditions. Demonstrating package integrity throughout these conditions strengthens confidence in product performance during its intended lifecycle.

Factors that can Influence Pharmaceutical Package Performance Over Time

Pharmaceutical package performance can change due to various storage and environmental factors.

• Temperature Variations: Repeated heating and cooling cycles can affect packaging materials, seals, and closure systems.
• Humidity Exposure: Moisture can influence barrier properties and affect moisture-sensitive pharmaceutical products.
• Oxygen Ingress: Oxygen entering through package defects may contribute to product degradation or oxidation.
• Light Exposure: Prolonged exposure to UV or visible light can affect certain drug formulations and packaging materials.
• Transportation and Handling: Vibration, shock, and mechanical stress during shipping may influence package integrity.
• Storage Conditions: Refrigerated, frozen, and ultra-low-temperature environments can place additional stress on packaging systems.
• Packaging Material Properties: Glass, polymers, elastomers, foils, and laminates respond differently over extended storage periods.
• Seal and Closure Performance: Changes in sealing interfaces or closure components may affect long-term package integrity.
• Package Design and Geometry:Container shape, headspace volume, and closure configuration can influence package performance.
• Manufacturing Process Variations: Differences in sealing parameters or assembly processes may affect package consistency over time.

Which Testing Methods Are Commonly Used for Pharmaceutical Packaging?

Benefits of Package Testing for Pharmaceutical Shelf-Life Claims

Conclusion

Frequently Asked Questions

Container Closure Integrity Testing (CCIT) has become an established practice for verifying the ability of pharmaceutical packaging to prevent unwanted ingress or product loss. As packaging systems become increasingly diverse, manufacturers require inspection methods capable of identifying extremely small leaks across a wide variety of container formats.

Among deterministic CCIT technologies, Vacuum Decay and Helium Leak Detection are frequently selected because of their sensitivity and repeatable performance. Although both methods evaluate package integrity, they operate using different principles and are suited to different applications. Understanding these differences helps manufacturers select a testing approach that aligns with packaging design, product characteristics, and validation objectives.

Why is Choosing the Right CCIT Method Important?

Selecting an appropriate CCIT method begins with understanding the characteristics of the package being evaluated. Packaging material, container geometry, closure configuration, product type, allowable leakage limits, and validation objectives all influence method selection. A testing method that aligns with these factors can generate repeatable results while providing meaningful information about package integrity. Choosing a suitable approach during product development can simplify validation activities and reduce unnecessary testing later in the product lifecycle. It also allows manufacturers to evaluate package performance under realistic conditions while meeting regulatory expectations outlined in USP <1207>. Since no single technology addresses every application, selecting the right method contributes to more reliable package evaluation across different pharmaceutical packaging systems.

What is Vacuum Decay Technology?

Vacuum Decay is a deterministic, non-destructive Container Closure Integrity Testing (CCIT) method used to detect leaks in sealed pharmaceutical and medical device packaging. Recognized by ASTM F2338 and referenced in USP <1207>, the technology is based on measuring pressure changes within a controlled vacuum environment rather than relying on subjective visual observations. It is widely used during package development, validation, stability studies, and routine quality inspection because it can identify extremely small leaks with high sensitivity and repeatability.

During testing, the package is placed inside a specially designed test chamber that closely matches its size and shape. Once the chamber is sealed, a predefined vacuum level is applied, creating a pressure differential between the inside of the package and the surrounding chamber. If the package contains a leak, air or gas escapes through the defect, causing measurable pressure changes inside the chamber. Highly sensitive pressure transducers continuously monitor these changes throughout the test cycle. The technology delivers fast test cycles, high repeatability, and objective digital results, making it suitable for laboratory testing as well as production quality programs. Because the method directly measures package integrity without introducing additional materials into the package, it has become one of the most widely adopted deterministic technologies for pharmaceutical container closure integrity testing.

What Types of Packaging Can Vacuum Decay Test?

Vacuum Decay is suitable for numerous pharmaceutical packaging formats, including:

• Blister packages
• Flexible pouches
• Rigid containers (vials, syringes, bottles)
• Semi-rigid containers
• Medical device packaging
• Unit-dose packaging
• Combination product devices (autoinjectors)
• Trays and thermoformed packages

Modern Vacuum Decay systems can accommodate different package sizes through configurable test chambers, making the technology suitable for both laboratory and production environments.

What Is Helium Leak Detection?

Helium Leak Detection is a deterministic Container Closure Integrity Testing (CCIT) method that uses helium as a tracer gas to identify and measure leaks in pharmaceutical packaging with exceptional sensitivity. Recognized in USP <1207>, the technology is widely used during package development, validation, engineering studies, and applications requiring quantitative leak-rate measurement. Unlike methods that evaluate pressure changes within a test chamber, Helium Leak Detection measures the actual flow of helium escaping through defects.

The technology operates by introducing helium into or around the test package under controlled conditions. Depending on the testing approach, the package may be filled with helium before sealing or exposed to a helium-rich environment. The package is then placed inside a vacuum chamber connected to a highly sensitive helium mass spectrometer. If a leak is present, helium molecules pass through the defect and are drawn into the mass spectrometer, where they are detected and measured. The instrument converts this measurement into a quantitative leak rate, typically expressed in units such as mbar L/s.

What Types of Packaging Can Helium Leak Test?

Helium Leak Detection can evaluate a broad range of pharmaceutical packaging, including:

• Glass vials
• Pre-filled syringes
• Bottles
• Cartridges
• Medical device packaging
• Blister packs
• High-value biologic packaging
• Foil pouches
• Combination products

The technology is also suitable for packages intended for cold-chain and ultra-low-temperature storage where quantitative leak-rate data may be required.

How Do Vacuum Decay and Helium Leak Detection Differ?

Although both Vacuum Decay and Helium Leak Detection are deterministic CCIT methods, they differ in several practical aspects beyond their operating principles. One of the most noticeable differences is sample handling. Vacuum Decay is a non-destructive technique, allowing tested packages to remain intact for additional testing, stability studies, or future evaluation. In contrast, Helium Leak Detection is generally considered a destructive method because packages require helium charging or specialized preparation before testing and typically cannot be returned to their original condition.

The type of results generated also differs. Vacuum Decay produces a pass/fail assessment based on measured pressure changes, making it well suited for routine package evaluation. Helium Leak Detection provides quantitative leak-rate values, allowing manufacturers to characterize package performance, compare sealing processes, and establish acceptable leakage limits during development.

Testing efficiency is another consideration. Vacuum Decay typically involves simpler test preparation and faster inspection cycles, making it suitable for evaluating larger numbers of samples. Helium Leak Detection generally requires additional sample preparation, tracer gas handling, and specialized instrumentation, which may increase testing time but provides highly detailed analytical data.

Are There Situations Where One Method Is Always Better?

There is no single CCIT method that is suitable for every pharmaceutical packaging application. The selection of Vacuum Decay or Helium Leak Detection should be based on the purpose of testing, the level of sensitivity required, package configuration, and the type of data needed.

Vacuum Decay is often selected when manufacturers require non-destructive testing with high throughput for routine quality inspection, process validation, and stability studies. Since tested samples remain intact, they can be retained for additional evaluation or long-term studies. The method is also well suited for applications involving larger sample sizes and repeated testing.

Helium Leak Detection is generally preferred when quantitative leak-rate measurements are needed to characterize package performance or establish Maximum Allowable Leakage Limits (MALL). Its exceptionally high sensitivity makes it valuable for research and development, package optimization, failure analysis, and applications involving high-value pharmaceutical products. Because the method is typically destructive, it is less commonly used for routine production sample inspection.

In many pharmaceutical development programs, the two technologies are not viewed as competing alternatives. Instead, they are used at different stages of the product lifecycle, with each contributing information that addresses specific testing objectives. Selecting the most appropriate method involves balancing package characteristics, study goals, sample availability, and regulatory expectations.

Conclusion

Vacuum Decay and Helium Leak Detection are well-established deterministic technologies that address different container closure integrity testing requirements. While both methods can detect extremely small leaks, their testing approaches, sample handling, and output differ significantly. Vacuum Decay offers non-destructive inspection suitable for repeated package evaluation, whereas Helium Leak Detection delivers highly sensitive quantitative leak-rate data through a destructive testing approach.

A thorough understanding of package design, testing objectives, sensitivity requirements, and validation strategy helps manufacturers determine which technology best fits a specific application. Matching the testing method to the intended purpose enables consistent integrity assessment throughout pharmaceutical package development and quality evaluation.

Frequently Asked Questions

1. Is Vacuum Decay suitable for flexible packaging?

Yes. Vacuum Decay can evaluate rigid, semi-rigid, and flexible packaging formats when appropriate test parameters and chamber configurations are used. It is commonly applied to pouches, blister packs, trays, and other sealed package designs.

2. Why is quantitative leak-rate measurement useful?

Quantitative leak-rate measurement provides numerical data that can be used to compare package designs, evaluate sealing processes, investigate package performance, and establish Maximum Allowable Leakage Limits (MALL) during product development.

3. What factors should be considered when selecting a CCIT method?

Method selection is influenced by package design, packaging material, product characteristics, required sensitivity, testing objectives, sample availability, regulatory expectations, and whether non-destructive or destructive testing is preferred.

When people think about pharmaceutical products, their attention is often drawn to the drug formulation, manufacturing process, or clinical performance. Yet, one component quietly works behind the scenes from the moment a product is filled until it reaches the patient—the packaging or container.

Pharmaceutical packaging serves as the first line of defense against environmental exposure, contamination, physical damage, and product loss. Whether protecting a sterile injectable, a biologic, a vaccine, or a solid oral dosage form, the packaging system is expected to preserve product quality throughout manufacturing, storage, transportation, and distribution.

Although it rarely receives the same attention as the medicine itself, packaging performs a continuous protective role throughout the product's lifecycle. This is why it is often described as the "silent bodyguard" of pharmaceutical products.

Why is Pharmaceutical Packaging Often Called the Silent Bodyguard?

Pharmaceutical packaging performs its protective function without drawing attention to itself. Once a product leaves the manufacturing line, the package continuously shields it from external factors that could compromise its quality.

Depending on the product, the packaging system may help protect against:

• Moisture
• Oxygen
• Light
• Microbial contamination
• Physical damage
• Product leakage
• Environmental exposure
• Handling during transportation and distribution

Unlike active manufacturing processes, packaging works continuously without intervention. If it performs as intended, the product remains protected throughout its shelf life. If the packaging system fails, however, product quality, stability, and sterility may be affected.

For this reason, pharmaceutical packaging is much more than a container—it is an integral component of the overall product protection strategy.

What Types of Pharmaceutical Packaging Are Commonly Used?

Pharmaceutical products are packaged in a variety of formats, each designed to meet specific product and performance requirements.

Common packaging formats include:

• Glass vials
• Pre-filled syringes
• Ampoules
• Cartridges
• Blow-Fill-Seal (BFS) containers
• Plastic bottles
• Flexible IV bags
• Blister packs
• Sachets
• Pouches
• Combination product packaging

The choice of packaging depends on several factors, including the dosage form, route of administration, product sensitivity, sterilization method, storage conditions, and intended shelf life.

Each packaging format presents unique design considerations and validation requirements to ensure that it consistently protects the product.

Challenges Faced by Pharmaceutical Packaging

• Moisture and Oxygen Exposure: Many pharmaceutical products, particularly biologics and moisture-sensitive formulations, can be affected by even small amounts of moisture or oxygen entering the package.
• Temperature Variations: Products may encounter refrigerated, frozen, ultra-cold, or elevated temperatures during storage and transportation. Packaging materials and seals must continue to perform under these varying conditions.
• Transportation and Distribution: Shipping subjects packages to vibration, compression, impact, and repeated handling. These stresses can influence packaging performance if not properly considered during development and validation.
• Sterilization Processes: Packaging used for sterile products may undergo sterilization methods such as steam, ethylene oxide, or radiation. These processes can affect packaging materials, seals, and closure systems.
• Long-Term Aging: Packaging must maintain its protective properties throughout the product's intended shelf life, even after prolonged storage under controlled environmental conditions.

Container Closure Integrity: A Fundamental Requirement

Container Closure Integrity (CCI) is a fundamental requirement because it demonstrates that a pharmaceutical packaging system can maintain an effective barrier against contamination and environmental exposure throughout the product's lifecycle. Sterile drug products rely on the container closure system to prevent the unintended ingress of microorganisms, moisture, oxygen, and other contaminants, while also preventing product leakage. Even microscopic defects in a seal, stopper, or container can create leak pathways that may affect product sterility, stability, and overall quality over time. As a result, manufacturers evaluate container closure integrity during package development, validation, stability studies, and routine quality assurance to verify that the packaging continues to perform as intended under expected storage, transportation, and distribution conditions. By generating objective evidence of package performance, Container Closure Integrity Testing (CCIT) supports informed quality decisions and provides greater confidence in the long-term reliability of pharmaceutical packaging.

Which Technologies Help Verify Package Integrity?

Vacuum Decay Technology

Vacuum Decay Technology is a deterministic, non-destructive Container Closure Integrity Testing (CCIT) method used to evaluate the integrity of sealed pharmaceutical packaging systems. During testing, the package is placed inside a chamber where a controlled vacuum is applied. Highly sensitive pressure sensors monitor for changes that may indicate the presence of a leak. The technology provides quantitative, repeatable, and objective results without damaging the package, making it suitable for package development, validation, stability studies, and routine quality assurance. Vacuum Decay can be used with a wide range of rigid, semi-rigid, and flexible pharmaceutical packaging formats, including vials, bottles, pouches, trays, and Blow-Fill-Seal (BFS) containers.

High Voltage Leak Detection (HVLD)

High Voltage Leak Detection (HVLD) is a deterministic, non-destructive inspection technology designed for liquid-filled pharmaceutical containers. The method applies a controlled high-voltage electrical potential across the package and measures changes in electrical conductivity that may indicate defects such as cracks, pinholes, or incomplete seals. By utilizing the conductive properties of liquid-filled products, HVLD can accurately identify defects in container walls and closure systems without compromising the package. The technology is commonly used for liquid-filled vials, prefilled syringes, ampoules, and cartridges, supporting package development, validation, and production inspection.

Helium Leak Detection

Helium Leak Detection is a highly sensitive deterministic testing method that uses helium as a tracer gas and a mass spectrometer to detect and quantify microscopic leaks in pharmaceutical packaging. During testing, helium is introduced into or around the package, and any helium escaping through a leak path is measured by the mass spectrometer to determine the leak rate. Because helium is inert, non-reactive, and capable of passing through extremely small defects, the technology can identify sub-micron leaks that may not be detected by conventional testing methods. Helium Leak Detection is widely used during package development, method validation, leak characterization, and applications requiring highly sensitive quantitative leak-rate measurements.

Airborne Ultrasound

Airborne Ultrasound is a non-destructive seal quality inspection technology used primarily for evaluating seal quality in flexible packaging systems. The method transmits high-frequency ultrasonic waves through the sealed area and analyzes how the signals pass through the materials to identify inconsistencies that may indicate defects in the seal. It can detect seal-related issues such as channel leaks, seal contamination, wrinkles, folds, weak bonds, and incomplete seals that may not be visible during routine visual inspection. Airborne Ultrasound is commonly applied to medical device pouches, Tyvek® packaging, blister packs, trays, sachets, and other flexible packaging formats, providing objective and repeatable information to support packaging validation, process optimization, and routine quality inspections.

Conclusion

Pharmaceutical packaging truly earns its reputation as the silent bodyguard. While it may not receive the same attention as the medicine it protects, its role is continuous and indispensable. From shielding products against moisture, oxygen, contamination, and physical damage to maintaining sterility and stability throughout storage and distribution, packaging serves as a constant safeguard for product quality.

As pharmaceutical products become increasingly complex, the expectations placed on packaging systems continue to grow. Careful package design, comprehensive validation, and ongoing performance evaluations are all essential for ensuring that packaging continues to perform as intended.

Technologies such as Vacuum Decay, High Voltage Leak Detection, Helium Leak Detection, and Airborne Ultrasound provide manufacturers with objective ways to evaluate package integrity and seal quality. When combined with a well-planned packaging strategy, these technologies help build confidence that pharmaceutical products remain protected from production through patient use.

Frequently Asked Questions

1. Why is pharmaceutical packaging called the silent bodyguard?

Pharmaceutical packaging continuously protects the product from contamination, moisture, oxygen, light, physical damage, and environmental exposure throughout its lifecycle, often without being noticed unless a failure occurs.

2. What is Container Closure Integrity?

Container Closure Integrity refers to a package's ability to maintain an effective barrier against air, moisture, microorganisms, gases, and product leakage throughout storage and distribution.

3. Why isn't visual inspection sufficient for package evaluation?

Visual inspection may not identify microscopic defects such as channel leaks, pinholes, seal contamination, incomplete seals, or hairline cracks. Specialized package integrity testing methods are often used to evaluate these conditions.

Packaging validation is one of the most important activities in pharmaceutical product development. A well-designed packaging system protects the drug product from contamination, moisture, oxygen, light, and physical damage while maintaining its quality throughout storage, transportation, and distribution. However, validating a packaging system involves much more than confirming that a package can be filled and sealed.

Successful packaging validation requires a thorough understanding of packaging materials, sealing processes, product compatibility, environmental conditions, and package performance over time. It also requires manufacturers to generate objective evidence that the packaging system consistently performs as intended.

Despite advances in packaging technologies and testing methods, many organizations still encounter avoidable validation challenges. These mistakes can lead to additional testing, delayed product launches, increased development costs, and quality investigations.

Understanding the most common packaging validation mistakes—and how to avoid them—can help manufacturers build more reliable packaging programs.

What is Pharmaceutical Packaging Validation?

Packaging validation is the documented process of demonstrating that a pharmaceutical packaging system consistently protects the product throughout its intended lifecycle.

A comprehensive validation program typically evaluates:

• Packaging materials
• Container closure systems
• Sealing processes
• Product-package compatibility
• Container Closure Integrity (CCI)
• Seal quality
• Transportation performance
• Environmental resistance
• Stability performance
• Manufacturing consistency

Rather than being a single event, packaging validation begins during product development and continues through commercial manufacturing.

Why is Packaging Validation Important?

Reliable packaging validation helps manufacturers demonstrate that their packaging systems consistently protect pharmaceutical products throughout manufacturing, storage, transportation, and distribution. A comprehensive validation program supports product quality by verifying that the packaging maintains sterility, preserves product stability, and performs as intended under expected conditions. It also helps reduce packaging-related risks, improve manufacturing consistency, and generate objective data that supports regulatory submissions and quality assurance activities. By identifying potential packaging issues early in the development process, manufacturers can address them before commercial production, minimizing costly redesigns, reducing project delays, and building greater confidence in overall package performance.

Common Mistakes Companies Make in Packaging Validation

Mistake 1: Waiting Until Late in Product Development

One of the most common mistakes is postponing packaging validation until the final stages of product development.

Late validation often results in:

• Packaging redesigns
• Additional qualification studies
• Delayed regulatory submissions
• Higher development costs
• Extended commercialization timelines

Early integration of packaging validation allows manufacturers to identify design issues before they become expensive problems.

Mistake 2: Treating Validation as a One-Time Activity

Validation is not completed after initial qualification. Packaging processes evolve due to:

• Equipment maintenance
• Material supplier changes
• Manufacturing improvements
• Process optimization
• Facility modifications

Without periodic review and revalidation, previously qualified processes may no longer operate within acceptable limits.

Mistake 3: Selecting Packaging Materials Without Adequate Evaluation

Choosing packaging materials based primarily on cost can compromise long-term package performance.

Manufacturers should evaluate:

• Moisture barrier properties
• Oxygen transmission rates
• Chemical compatibility
• Mechanical strength
• Sterilization compatibility
• Shelf-life performance

Comprehensive material qualification minimizes the likelihood of future packaging failures.

Mistake 4: Overlooking Container Closure Integrity Testing (CCIT)

Many validation programs emphasize visual inspection while giving insufficient attention to container closure integrity.

Microscopic leaks may remain undetected using visual methods alone.

Deterministic CCIT technologies provide quantitative measurements capable of detecting extremely small leaks before they affect product quality.

Including CCIT strengthens packaging validation by demonstrating that container closure systems maintain integrity throughout their lifecycle.

Mistake 5: Using Destructive Test Methods Exclusively

Traditional destructive testing often limits sample availability and prevents repeat evaluations on the same package.

Non-destructive technologies offer several advantages:

• Repeat testing on identical samples
• Higher statistical confidence
• Reduced product waste
• Improved process monitoring
• Enhanced investigation capabilities

These benefits support more efficient validation studies while conserving valuable pharmaceutical products.

Consequences of Poor Packaging Validation

Inadequate packaging validation can create significant operational, financial, and regulatory challenges.

Potential consequences include:

• Product Quality Issues: Packaging failures may expose products to moisture, oxygen, microorganisms, or contaminants that compromise product quality.
• Regulatory Observations: Incomplete validation documentation or insufficient scientific justification may result in inspection findings, warning letters, or delayed approvals.
• Product Recalls: Packaging defects identified after commercial release may require product recalls, affecting both manufacturers and patients.
• Increased Manufacturing Costs: Corrective actions, repeat validation studies, investigations, and production downtime increase overall operating expenses.
• Supply Chain Disruptions: Packaging failures can interrupt manufacturing schedules and delay product availability in the market.
• Brand Reputation Damage: Consistent packaging quality supports customer confidence. Packaging failures can negatively affect brand reputation and market trust.

Best Practices for Successful Packaging Validation

A successful pharmaceutical packaging validation program requires a proactive, science-based approach that extends throughout the product lifecycle. Rather than treating validation as a regulatory requirement alone, manufacturers should integrate it into product development to identify packaging challenges early and minimize costly changes later. Packaging materials should be thoroughly evaluated for compatibility with the drug product and their ability to withstand storage, transportation, and environmental conditions. Establishing well-defined validation protocols, acceptance criteria, and statistically justified sampling plans helps generate reliable and repeatable data.

Manufacturers should incorporate deterministic Container Closure Integrity Testing (CCIT) methods where appropriate to the package format, product characteristics, and risk profile, providing objective and quantitative evidence of package integrity.

Evaluating packaging systems under worst-case conditions—including temperature fluctuations, humidity exposure, transportation stress, and long-term aging—helps demonstrate packaging robustness throughout the product's intended shelf life. In addition, maintaining comprehensive validation documentation, qualifying packaging material suppliers, monitoring critical process parameters, and conducting periodic reviews or revalidation following significant process or material changes contribute to consistent packaging performance. Regular personnel training and continuous process monitoring further strengthen validation programs by supporting compliance, reducing variability, and improving overall product quality.

Conclusion

Pharmaceutical packaging validation is a lifecycle process that demonstrates a packaging system can consistently protect the product throughout manufacturing, storage, transportation, distribution, and its intended shelf life.

Avoidable mistakes such as delaying validation, overlooking Container Closure Integrity Testing (CCIT), relying solely on destructive test methods, or failing to adequately evaluate packaging materials can increase development costs, delay regulatory approvals, and compromise product quality.

By adopting a proactive, science- and risk-based approach to packaging validation, manufacturers can build more robust and reliable packaging systems from development through commercialization. Integrating comprehensive package evaluation, deterministic CCIT where appropriate, sound documentation, and ongoing lifecycle monitoring helps support regulatory compliance, improve manufacturing consistency, reduce packaging-related risk, and provide greater confidence that pharmaceutical products will maintain their quality, safety, and performance throughout their intended shelf life.

As pharmaceutical packaging continues to evolve with complex delivery systems, biologics, and combination products, robust packaging validation and scientifically justified Container Closure Integrity Testing play an increasingly important role in demonstrating package performance and supporting product quality throughout the product lifecycle.